Keyword: AstraZeneca

Now well on its way to becoming a multiproduct company, Seattle Genetics has decided the time is right to bring in its first chief commercial officer.

AstraZeneca has released data showing its med's effects can last up to two years in severe asthma.

When it comes to CLL, AZ is looking to push Imbruvica aside with newcomer Calquence. But based on some new data, one analyst doesn’t see it happening.

After Eli Lilly’s Cyramza flopped a liver cancer trial five years ago, the drugmaker’s chances in the field looked slim. That all changed Monday.

Takeda sells meds to Novartis and J&J; Daiichi's AZ-shared HER2 antibody-drug conjugate hits key trial goal; Sun scouts for Chinese partner.

As drugmakers count on their growing SGLT2 diabetes drugs, researchers are tracking cases of a flesh-eating genital infection in patients using them.

AstraZeneca and pro golfer Jason Day have teamed up on a campaign to encourage biomarker testing for lung cancer patients.

Chasing big fish in the BTK inhibitor market, AstraZeneca’s Calquence was looking for a leg up. New clinical data show promise in leukemia.

After Moderna's massive IPO in December, the drugmaker's CEO, Stéphane Bancel, earned a pay package worth $58.6 million.

AZ warns of slower China growth; BeiGene chief ranks among highest-paid biopharma CEOs; Kangmei faces delisting over huge accounting "error."